Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has closed its previously announced registered direct offering ...

Hims & Hers Health, Inc. is a dramatically undervalued company if your holding period can be measured in decades. Read more ...

Pursuing the world's first-ever orally-dosed liraglutide KELOWNA, BC / ACCESS Newswire / February 20, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global ...

Novo Nordisk thrives despite competition and explore its breakthrough amycretin study. Read here to know why we rate NVO ...

HealthDay News — Age differences are seen in the efficacy of treatments for type 2 diabetes, according to a study published online Feb. 3 in the Journal of the American Medical Association.

Conference Call Scheduled for 9 a.m. EDT Today - EXTON, Pa., Feb. 13, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced its ...

A small semaglutide trial suggests the medicine's suppression of appetite may extend to alcohol, but larger tests are needed ...

McKesson MCK delivered an 18% increase in revenues ($95.3 billion) and a 16% rise in adjusted operating profit during the ...

US stocks were mixed on Thursday in anticipation of Amazon's quarterly results, as investors assessed the earnings season so ...

Max Verstappen and Michael Schumacher are responsible for two of the best seasons in Formula 1 history. Between 2000 and 2004 ... Photo by PATRICK HERTZOG/AFP via Getty Images However, it’s unfair to ...

After just a few years on the market, a new wave of GLP-1 drugs approved for weight loss have upended what we know about obesity. By now, these are household names: Mounjaro. Wegovy. Zepbound ...

A final-stage study has found that exenatide, a GLP-1 drug used to treat Type 2 diabetes, showed no benefit in slowing the progression of Parkinson's disease. The 96-week trial, published in The ...